IN8bio (INAB)
(Delayed Data from NSDQ)
$0.33 USD
+0.02 (8.12%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $0.34 +0.01 (2.94%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for IN8bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 29 | 15 | 9 | 5 |
Income After Depreciation & Amortization | -30 | -29 | -15 | -9 | -5 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -30 | -29 | -15 | -9 | -5 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -29 | -15 | -9 | -5 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -29 | -15 | -9 | -5 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -28 | -27 | -14 | -8 | -5 |
Depreciation & Amortization (Cash Flow) | 3 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -30 | -29 | -15 | -9 | -5 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 29.87 | 20.97 | 9.97 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.00 | -1.36 | -1.47 | NA | NA |
Diluted Net EPS (GAAP) | -1.00 | -1.36 | -1.47 | -3.02 | NA |
Fiscal Year end for IN8bio, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 8.69 | 8.64 | 7.60 | 7.17 | 7.71 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.69 | -8.64 | -7.60 | -7.17 | -7.71 |
Non-Operating Income | 0.06 | 0.08 | 0.33 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -8.63 | -8.56 | -7.60 | -7.17 | -7.72 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.63 | -8.56 | -7.60 | -7.17 | -7.72 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.63 | -8.56 | -7.60 | -7.17 | -7.72 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 45.13 | 43.29 | 35.80 | 31.55 | 28.47 |
Diluted EPS Before Non-Recurring Items | -0.19 | -0.20 | -0.21 | -0.23 | -0.27 |
Diluted Net EPS (GAAP) | -0.19 | -0.20 | -0.20 | -0.23 | -0.27 |